Porównaj metody

	Addenbrooke's Cognitive Examination	Skala Oceny Choroby Alzheimera – Funkcje Poznawcze
Dziedzina	Neuropsychologia	Neuropsychologia
Rodzina	Process / pipeline	Process / pipeline
Rok powstania	2000	1984
Twórca	Padasalai Mathuranath	William Rosen
Typ	Clinician-administered comprehensive cognitive examination	Clinician-administered cognitive scale for Alzheimer's disease
Źródło pierwotne	Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000). A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 55(11), 1613-1620.	Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141(11), 1356-1364.
Inne nazwy	ACE, ACE-R, ACE-III, Addenbrooke Cognitive Examination	ADAS-Cog, ADAS-Cog14, ADAS-Cog13
Pokrewne	5	5
Podsumowanie	The Addenbrooke's Cognitive Examination (ACE) is a brief yet comprehensive clinician-administered cognitive battery designed to assess multiple cognitive domains and differentiate between types of dementia. Originally developed by Mathuranath and colleagues at Cambridge University in 2000, the ACE was created to address limitations of single-domain screening tools. The revised version (ACE-R, 2006) and further refined version (ACE-III, 2013) provide updated norms and improved sensitivity. The ACE-R and ACE-III are particularly valuable for distinguishing Alzheimer's disease from frontotemporal dementia.	The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is a clinician-administered cognitive assessment instrument designed specifically to measure cognitive decline in Alzheimer's disease. Developed by Rosen, Mohs, and Davis in 1984 and published in the American Journal of Psychiatry, the ADAS-Cog has become the gold standard outcome measure in pharmaceutical trials of antidementia drugs. It is sensitive to disease progression and capable of detecting cognitive change over periods as brief as 6–12 months.